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Background: Despite administration of annual influenza vaccination, influenza-associated complications in transplant
recipients continue to be an important cause of hospitalization and death. Although influenza vaccination has been
proven to be the most effective measure to reduce influenza infection after transplantation, transplant recipients are
still vulnerable to influenza infections, with lower serological responses to vaccination compared to the general
population. In order to assess the efficacy and safety of an alternative immunization scheme for solid organ transplant
recipients, the TRANSGRIPE1-2 Study Group aimed to test a booster dose administration 5 weeks after the standard
vaccination. The primary objective of this trial was to compare short-term and long-term neutralizing antibody
immunogenicity of a booster dose of influenza vaccination to the standard single-dose immunization scheme.
Secondary objectives included the evaluation of the efficacy and/or safety, cellular immune response, incidence of
influenza infection, graft rejection, retransplant and mortality rates.
Methods/Design: This phase III, randomized, controlled, open-label clinical trial was conducted between October 2012
and December 2013 in 12 Spanish public referral hospitals. Solid organ transplant recipients (liver, kidney, heart or lung),
older than 16 years of age more than 30 days after transplantation were eligible to participate. Patients (N = 514) were
stratified 1:1 by center, type of organ and time after transplantation and who either received the standard single dose
(n = 257) or were treated according to a novel influenza vaccination schedule comprising the administration of a
booster dose 5 weeks after standard vaccination (n = 254). Seroconversion rates were measured as a determinant of
protection against influenza (main outcome). Efficacy and safety outcomes were followed until 1 year after influenza
vaccination with assessment of short-term (0, 5, 10 and 15 weeks) and long-term (12 months) results. Intention-to-treat,
per-protocol and safety analyses will be performed.
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Discussion: This trial will increase knowledge about the safety and efficacy of a booster dose of influenza vaccine in
solid organ transplant recipients. At the time the manuscript was submitted for publication, trial recruitment was closed
with a total of 499 participants included during a 2-month period (within the seasonal influenza vaccination campaign).
Trial registration: ClinicalTrials.gov Identifier: NCT01761435 (registered 13 December 2012).
EudraCT Identifier: 2011-003243-21 (registered 4 July 2011).
Keywords: Influenza prevention, Influenza vaccination, Randomized trial, Solid organ transplantBackground
Influenza is a contagious, acute, usually self-limited febrile
illness caused by infection with influenza A or B virus that
occurs during variable severity outbreaks every winter.
Solid organ transplant (SOT) recipients have been reported
to be more susceptible to influenza virus [1,2] compared
to the general population. Notwithstanding current
vaccination protocols, influenza-associated morbidity
and mortality continue to be an important cause of
hospitalization and death in SOT recipients [3,4]. Influenza
infection in this group of patients is associated with
significant short-term and long-term complications,
such as pneumonia, long viral shedding, graft rejection
and death [3,5-9]. Thus, efforts are needed to reduce
the incidence of influenza in this especially vulnerable
population.
One of the most effective proven measures to reduce
the incidence and complications of influenza infection is
seasonal influenza vaccination. This strategy has been
shown to reduce the risk of graft rejection and death
during the first year after transplantation [10]. Although
the results of some studies are discordant [11-20],
decreased serological responses to influenza vaccination
in SOT recipients, compared to the general population,
have been reported in most studies.
Despite increasing vaccine coverage throughout the
2010–2011 influenza season, rates of influenza-associated
mortality (7.2%) and ICU hospitalization (16.2%) in SOT
recipients remained high [21]. Several strategies have been
evaluated to improve the efficacy of vaccination in SOT
recipients, including the use of higher doses of antigen,
administration of adjuvanted vaccines and intradermal
route of administration [19,22-26]. However, these
strategies have been assessed only in small cohorts;
thus, no clear recommendation can be provided at
this time.
Detectable antibody titers against influenza at baseline
have been associated with higher postvaccination antibody
responses [15,20]. However, an annual influenza vaccination
to maintain baseline antibody titers that may boost yearly
vaccine efficacy may not be sufficient in SOT recipients,
because only 30% of SOT recipients maintain detectable
neutralizing antibody titers 1 year after vaccination [27].
This may be due either to immunosuppressive regimensthat, although critical for preventing acute rejection,
deplete the adaptive arm of the immune system, or to
seasonal vaccine strain modifications that may decrease
immunogenicity. A booster dose given some weeks after
the standard dose may elicit a long-lasting antibody
response, thus producing better protection in current and
subsequent influenza seasons. The booster strategy has
been tested in several studies involving different types of
transplant recipients, but the results are as yet inconclusive
[28]. In addition, no randomized controlled trial has
addressed this issue to date.
The TRANSGRIPE 1-2 study is a publicly funded,
phase III, parallel-group, randomized clinical trial for the
evaluation of the safety and efficacy of a booster dose of
trivalent inactivated seasonal influenza vaccine administered
5 weeks after seasonal influenza vaccination compared to a
single dose of the vaccine administered to SOT recipients.
In the present study, we hypothesized that the efficacy of
seasonal trivalent inactivated influenza vaccination might be
significantly increased in SOT recipients by administering a
second booster dose 5 weeks after the standard single-dose
vaccination.
The primary objective of the present clinical trial is to
compare short-term immunogenicity by measuring neutral-
izing antibodies after a booster dose versus a standard single
dose of influenza vaccine in SOT recipients.
The following are the secondary objectives of the trial:
 To compare the long-term immunogenicity of
two doses versus a standard single-dose of influenza
vaccine
 To compare short-term and long-term
influenza-specific T-cell immune responses
among patients within both treatment arms
 To determine the clinical effectiveness of the
experimental vaccination scheme, measuring the
incidence of confirmed influenza infection
 To establish a safety intervention by analyzing
incidence of adverse events (AEs), mortality and
outcomes such as graft rejection
Moreover, TRANSGRIPE1-2 trial bears two associated
biological substudies in patients who provided specific
consent for additional investigations.
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The TRANSGRIPE1-2 study is a phase III, randomized,
controlled, open-label, multicenter clinical trial designed
to assess the safety and efficacy of a booster dose of
influenza vaccine in SOT outpatients. The study was
performed in 12 Spanish referral hospitals between
October 2012 and December 2013. The coordinating
center was Virgen del Rocío University Hospital, which
was responsible for handling clinical trial administrative
authorization and regulatory affairs, providing study
supplies, independent data and safety monitoring and
centralized laboratory immunological quantifications, as
well as general coordination and daily operational
management of the trial for all of the participating
sites. The study was authorized by the Spanish Regulatory
Authority and the Coordinating Institutional Review Board
of Biomedical Research in Andalusia (Acting as Research
Ethics Committee of reference), which gathered the
approval from the local ethics committees at all of the
participating sites: Virgen del Rocío University Hospital
Institutional Review Board (IRB), Seville; Reina Sof ía
University Hospital IRB, Córdoba; 12 de Octubre
University Hospital IRB, Madrid; Gregorio Marañón
General University Hospital IRB, Madrid; Ramón y
Cajal University Hospital IRB, Madrid; Vall d’Hebron
Hospital IRB, Barcelona; Bellvitge University Hospital
IRB, Barcelona; Barcelona Clinic Hospital IRB, Barcelona;
Cruces University Hospital IRB, San Vicente de Barakaldo;
La Fe University Hospital IRB, Valencia; Virgen Macarena
University Hospital IRB, Seville; and Marqués de Valdecillas
University Hospital IRB, Santander.
Selection and enrollment
The criteria for patient eligibility are detailed in Table 1.
Before the 2012–2013 flu vaccination campaign started,
patients were selected from the local SOT recipients lists
and invited to participate. Patients who met the selection
criteria and agreed to participate in the clinical trial by
signing an informed consent form were randomly assigned
to the intervention group and subjected to the study
protocol, including baseline extraction of blood samplesTable 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Solid organ transplant recipient
(liver, kidney, heart or lung)
Acute graft rejection within 15 days
before selection
Age ≥16 years Documented allergy and/or previous
intolerance and/or contraindication to
active compounds or excipients or any
traces and/or residues in the vaccine
At least 30 days posttransplant Previous medical record of any severe
and/or life-threatening adverse reaction
to the vaccine (such as Guillain-Barré
syndrome)
Signed informed consent form Confirmed pregnancy(prior to the administration of standard single-dose
influenza vaccination) for the quantification of baseline
cellular and humoral immune response.
Randomization
By 1:1 randomization, patients were allocated either
to receive the standard single-dose regimen or to be treated
according to a novel influenza vaccination schedule
comprising the administration of a booster dose 5 weeks
after the first vaccination dose. In order to avoid bias due to
differences in immunosuppression level of patients between
treatment arms, randomization was stratified according to
study sites (because local immunization protocols may
differ for SOT recipients), type of organ and time
since transplantation. Randomization was centralized
and computer-generated, with allocation concealed by
integrating a locked list into an electronic case report form
(eCRF). A copy of the randomization list is guarded in an
opaque, sealed envelope by the trial’s Central Management
Team (CMT)at the coordination center that is independent
from the investigators who recruited patients.
Trial intervention and control
Trivalent inactivated influenza vaccine containing
World Health Organization–recommended strains for the
Northern Hemisphere for the 2012–2013 season was
administered. The strains selected for inclusion in the
2012–2013 flu vaccines were an A/California/7/2009
(H1N1)pdm09-like virus, an A/Victoria/361/2011(H3N2)-
like virus and a B/Wisconsin/1/2010-like virus. The
vaccination scheme administered in the two treatment
arms is detailed in Table 2: standard intramuscular
influenza vaccination (treatment arm A) versus standard
vaccination followed by a second booster dose of the same
vaccine 5 weeks apart (treatment arm B).
The vaccine used for the trial was provided by the
Andalusian Health Service, and the pharmacy service
of the sponsor’s center was responsible for relabeling
and distributing the investigational medicinal product
(IMP), according to good manufacturing practices,
after obtaining necessary regulatory approval.
Despite the open-label design of the study, all immuno-
logic assays were carried out on coded and anonymous
specimens, and data analysts were blinded of which
intervention each patient received. During the study
period, patients received medical care based on existing
local protocols for transplant recipients. Any concomitant
medication recommended by clinical practice was
allowed within the clinical trial and was registered in
the study’s eCRF.
Follow-up protocol
Patients were followed up at the planned visits by
clinical teams at the participating centers, ensuring
Table 2 Treatment arms
Treatment arm Description
Standard influenza vaccination (treatment arm A) Single intramuscular 0.5-ml dose of inactivated influenza vaccine (split virion)
containing World Health Organization (WHO)–recommended strains in Northern
Hemisphere and European Union (EU) decision for the 2012–2013 season
(A/California/7/2009(H1N1)pdm09-like, A/Victoria/361/2011-like and
B/Wisconsin/1/2010-like strains, derived from B/Hubei- Wujiagang/158/2009)
Booster double-dose influenza vaccination
(treatment arm B)
Single standard intramuscular 0.5-ml dose of inactivated influenza vaccine
(split virion), followed by a second booster dose of the same vaccine 5 weeks
later;vaccine strain used was in compliance with the WHO recommendations
in Northern Hemisphere and EU decision for the 2012–2013 season
(A/California/7/2009(H1N1)pdm09-, A/Victoria/361/2011- and B/Wisconsin/1/2010-like
strains, derived from B/Hubei- Wujiagang/158/2009)
Martinez-Atienza et al. Trials 2014, 15:338 Page 4 of 10
http://www.trialsjournal.com/content/15/1/338that essential data about efficacy and safety were reg-
istered, and samples were collected (Figure 1). The
duration of the trial was 14 months: 2 months for patient
recruitment and 12 months of follow-up. Clinical, analytical
and exploratory data needed for the study were collected
and logged in the study’s eCRF at each follow-up visit. For
immunogenicity studies, patients’ blood samples were
collected at baseline prior to vaccination and at each
programmed visit after vaccination. Vaccine efficacy
was evaluated at baseline, midterm (5, 10 and 15 weeks
after immunization) and long-term (12 months after
immunization).
Neutralizing antibody levels for the three influenza
strains were measured using microneutralization assays,
and seroconversion rates were calculated. Influenza-specific
T-cell immune response was measured as the percentage of
CD4+ and CD8+ T cells secreting interferon γ in response
to influenza stimulation normalized to the negative control.514
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Figure 1 TRANSGRIPE 1-2 trial design and procedures. Clinical trial visi
evaluation and administration of the first dose of vaccine in arms A and B
weeks after inclusion (visit 3), short-term follow-up 10 weeks after inclusion
follow-up 12 months after the first dose of vaccine (visit 6). ImmunogenicitClinical trial visits were structured in five (or six) time
points as follows:
 Visits 1 and 2: Patient screening, baseline evaluation
and administration of the first dose of vaccine
(arms A and B). Protocols for visits 1 and 2 were
carried out in one visit when necessary.
 Visit 3: Five weeks after inclusion (range, 25 to
45 days) and administration of the second dose of
vaccine (arm B).
 Visit 4: Ten weeks after inclusion (range, 60 to 80 days).
 Visit 5: Fifteen weeks after inclusion (range, 95 to
115 days).
 Visit 6: Twelve months after inclusion (range, 11 to
13 months).
In the programmed visits, patients were prompted
to notify the clinician of the onset or continuation of2012-2013 Season Visit 6
city Evaluation
ty Evaluation
ts are structured in five (or six) time points: initial screening baseline
(visit 1 and 2), administration in arm B of second dose of vaccine 5
(visit 4) and 15 weeks after inclusion (visit 5), as well as long-term
y and drug safety were assessed at each programmed time point.
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the follow-up period or by email or telephone if symptoms
arose during the period between visits. In cases of symp-
toms, a nasopharyngeal swab was taken for detection of
influenza infection using RT-PCR assays.
Each participant had the right to withdraw consent
from the study at any point according to international
rules. Furthermore, a participant was removed from the
study at any time if any of the following withdrawal
criteria were met: noncompliance with study procedures
and requirements, such as not attending at least two
consecutive visits, or if clinical circumstances (for
example, AEs, comorbidities) required discontinuation of
the study medication or follow-up procedures according
to an investigator’s judgment. Patients who left the study
fulfilled the study procedure of premature finalization,
and AEs were followed until resolution. Statistical analysis
was carried out for all the patients who received the first
dose of influenza vaccine.
Study variables
Baseline variables regarding efficacy and safety are
described in Table 3 and were measured as appropriate
during the follow-up visits.
Outcome measures
Seroconversion rate was the primary end-point variable of
the study. Microneutralization assays were performed
to quantify neutralizing antibody titers against the
two influenza A strains and the influenza B strain.
Immunological response and vaccination efficacy were
based on the following international criteria: (1) geometric
mean titers (GMT; mean antibody titer in the group of
vaccinated individuals), (2) seroprotection rate (percentage
of patients with antibody titers ≥1:40), (3) seroconversion
rate (percentage of participants with four fold increase in
antibody titers from baseline) and (4) geometric mean ratioTable 3 Study variablesa
Category Variables
Demographic data Sex and age
Comorbidities COPD, diabetes, obesity, kid
disease, cerebrovascular dise
Previous vaccinations Influenza vaccination (season
pneumococcal conjugate va
Solid organ Transplant Date, organ, immunosuppre
Influenza infection records Confirmed influenza infectio
influenza severity, influenza
Immune response Seroconversion and seropro
responses, confirmed influen
Adverse events Dates, progress, intensity, ex
Concomitant treatments Indication, dose, frequency,
aCOPD, Chronic obstructive pulmonary disease; GMR, Geometric mean ratio; GMT, G(GMR; seroconversion factor postvaccination compared
with prevaccination). Neutralizing antibody titers were
evaluated at 5, 10 and 15 weeks and 1 year after influenza
vaccination. Cellular immune response to vaccination was
determined by quantifying influenza-specific CD4+ and
CD8+ memory cells at baseline, 15 weeks and 1 year after
influenza vaccination. For each treatment arm, clinical
efficacy was assessed by evaluating the episodes of
confirmed influenza infection during a 1-year follow-up
period. The safety endpoints at each evaluation time
frame were rejection episodes, hospitalization, graft loss,
mortality, incidence of AEs and severe AEs and rates of
discontinuation due to AEs.
In order to study in-depth the immune response to
influenza vaccination in SOT recipients, we will also
explore other genetic and biological outcomes in the
collected samples. Genetic expression patterns of immune
response and anti–human leukocyte antigen levels
induced by influenza vaccination will be analyzed as
ancillary outcomes.
Sample size calculation
Sample size was calculated using the results of a Spanish
multicenter study in which SOT recipients received
a single dose of seasonal influenza vaccination dur-
ing the 2010–2011 season [27]. In that study, sero-
conversion rates against influenza A(H1N1) 2009,
influenza A(H3N2) and influenza B were 77%, 67%
and 67%, respectively. According to these estimates, we
calculated our sample size according to the following
criteria:
 To achieve a 95% confidence level (significance
level of 5%) and 80% statistical power to observe
differences in testing the null hypothesis
(H0)p1 = p2 using a χ2 bilateral test in two
independent samples.ney failure, hepatic disease, AIDS, cancer, leukemia, connective tissue
ase, other comorbidities
s 2011–2012 and 2010–2011), influenza A H1N1 (2009) vaccination,
ccination, other immunizations
ssive treatment, graft rejection history, use of monoclonal antibodies
n in previous season, confirmed influenza infection after study treatment,
treatment, influenza treatment outcome, date of recovery
tection rates (GMT, GMR), influenza virus–specific memory A- and B-cell
za infection during follow-up
pectability, causality, progress, toxicity degree
administration route, start and end dates
eometric mean titers.
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10% (increased percentage of seroconversion rate in
the experimental arm), which is considered clinically
relevant in the literature. According to this criterion,
we would expect to achieve 77% and 87%
seroconversion rates in the control and experimental
arms, respectively.
 To estimate a 10% dropout rate per arm.
According to these premises, and using a 1:1 ratio of
experimental units to controls, the minimum number of
patients was set at 231 units in each treatment arm, with
a total of 462 evaluable participants to be recruited for
the study. Taking into account the estimated loss
percentage, the total number of patients needed for the
study was set at 514 (257 participants per treatment arm).
Sample size was calculated using the online Simple
Interactive Statistical Analysis calculator [29].
Statistical analysis
Every effort was made to promote study execution
consistency at each participating center with independ-
ent monitoring visits to oversee the progress of the trial,
ensuring that it was conducted, recorded and reported
in accordance with the protocol, standard operating
procedures (SOPs), good clinical practice (GCP) and
the applicable regulatory requirements.
Both intention-to-treat (ITT) and per-protocol analyses
will be performed. The ITT analysis will include all
patients who agreed to participate in the study, signed
informed consent forms, were randomized and received
the first vaccination dose. Per-protocol analysis will
include patients who were randomized, received the
vaccine according to the assigned scheme (either standard
single-dose vaccination in arm A or standard vaccination
followed by a booster dose 5 weeks later) and were
followed-up, excluding those who discontinued the trial
and those for whom severe protocol deviations (violations)
were registered. Safety analyses will be performed on
the safety population, comprising randomized patients
receiving at least the first dose of the influenza
vaccine. The safety population is thus equivalent to
the ITT population.
The first clinical trial data will be summarized using
descriptive statistics. Demographic data at baseline will be
analyzed. Other baseline characteristics, including type
and date of transplant, basal comorbidities, and immuno-
suppressive scheme, will be reported for each patient.
Summary tables (descriptive statistics and/or frequency
tables) will be provided for all baseline variables, efficacy
variables and safety variables, as appropriate. A descriptive
analysis of continuous variables will be performed
(number of patients, mean, standard deviation, range and
median). Ninety-five percent confidence highest posteriordensity intervals may also be presented if appropriate.
Frequency counts and percentage of participants within
each category will be provided for categorical data.
Efficacy analysis will be performed using sero-
conversion and seroprotection rates, GMT, GMR and
incidence of confirmed influenza infection (to assess
clinical effectiveness). The analysis will include, as
covariates, previous influenza vaccination, previous
record of confirmed influenza infection and other demo-
graphic and clinical variables. Additionally, a subgroup
analysis will be performed to evaluate effectiveness in pa-
tients with decreased response to influenza vaccination
(liver failure, use of mammalian target of rapamycin inhi-
bitors, first 6 months posttransplantation).
Vaccination safety analysis will be performed using
tabulations of AEs, and descriptive analysis will be pro-
vided at baseline and follow-up visits for each treatment
group. A tabulation of SAEs will also be provided for
each patient within each treatment group. The statistical
analysis will be performed by treatment phase (up to
30 days after vaccination) and for the posttreatment
phase (long-term follow-up), as appropriate. AEs will be
classified on the basis of Medical Dictionary for Regulatory
Activities (MedDRA) terminology and summarized for
each treatment arm. AE incidence rates will be summarized
by system organ class, preferred term, severity and
relationship to the IMP. The proportion of patients in
each treatment group reporting AEs that occur in ≥3% in
each treatment group will be compared using Bayesian
methods. The specific system organ classes and preferred
terms analyzed will be those reported by at least 5% of the
patients in each treatment group.
A bivariate analysis will be performed to compare
primary efficacy outcome, secondary efficacy and safety
endpoints between treatment arms of the study. A bivari-
ate analysis using a χ2 test or Fisher’s exact test will be
used for categorical variables, and the Bonferroni correc-
tion will be applied when appropriate. For quantitative var-
iables, the Mann–Whitney U test or Student’s t-test based
on their distribution will be used. If the variances are not
homogeneous (Levene test), the Welch test will be applied
(analysis of variance). The relative risks and 95% confi-
dence intervals (95% CI) will be calculated by taking the
exponent of the natural logarithm of the mean and 95%
CI. Also, the linear trend analysis will be used for multiple
comparisons. A multivariate model will be used to
adjust for possible confounding variables. The thresh-
old of statistical significance will be set at P < 0.05.
All reported P-values will be based on two-tailed
tests. We have optimized the design and conduct of
the trial to minimize the number of dropouts and
missing data. The analysis will be performed on the ITT
population, and missing data will be handled by imputing
missingness to failure.
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software (SPSS, Chicago, IL, USA). The TRANSGRIPE1-2
clinical trial has not been programmed with any interim
analysis or stopping rules, although the incidence of SAEs is
being monitored closely to detect a higher frequency of
their occurrence, which may require an early termination of
the trial.
Safety and adverse events report
In accordance with GCP, all AEs occurring during the
study, as observed by the investigator or reported by the
participant, regardless of whether attributed to study
medication, were monitored carefully and recorded on
the trial eCRFs. The following information was logged:
AE description (according to MedDRA terminology),
dates of onset and resolution, severity, assessment of
causality due to study medication, action taken and
other concomitant medications and procedures. Other
follow-up information was provided as necessary.
During the course of the clinical trial, investigators reported
any SAEs to the clinical monitor within 24 hours of onset.
The trial CMT (Central Management Team) was responsible
for reporting SAEs to the sponsor, regulatory authorities and
ethics committees within the required timelines.
The causality of AEs due to the study medication was
assessed by the principal investigator and reevaluated by a
qualified person responsible for pharmacovigilance who
was appointed by the trial’s CMT (Central Management
Team) and independent from the trial’s Scientific Coordin-
ation Team (SCT). The study’s pharmacovigilance monitor
was responsible for reviewing the accumulated data for par-
ticipant safety, and efficacy when appropriate, and for
making recommendations to the SCT concerning the con-
tinuation, modification or termination of the trial.
AEs related to the study medication, as judged by
the pharmacovigilance monitor, were followed until
resolution or until stable. All related AEs that resulted in a
participant’s withdrawal from the study or were present at
the end of the study will be followed until satisfactory
resolution. The decision whether an AE was of sufficient
severity to require participant removal from treatment
was left to the investigator’s clinical judgment. If this
happened, according to GCP rules, the participant was
asked to attend to an end-of-study assessment visit and
was given appropriate care under medical supervision
until symptoms ceased or became stable.
Project management
The trial is supported by the Clinical Trial Unit at
Virgen del Rocío University Hospital and was carried out
in accordancewith all relevant SOPs for the conduct,
management and monitoring of the study.
Strategic management of the trial was the responsibility
of the SCT, comprising the trial coordinating investigatorand the local research staff. The SCT was responsible for
supervising trial enrollment and patient follow-up and
offering practical clinical perspectives to assist study local
teams with medical aspects of the study implementation.
The SCT was also in charge of data management and
statistical analysis.
The Biomedicine Research Institute of Seville at the
coordinating trial site provided qualified research staff
and access to laboratory facilities to assist in sample
logistics, processing of samples, carrying out experi-
mental procedures and biological research and providing
expertise.
Operational management of the study was the responsi-
bility of the CMT, comprising the TRANSGRIPE1-2 project
manager, the clinical monitor, the person responsible for
pharmacovigilance, and the assisting research staff at the
clinical trial unit of the coordinating trial site. The CMT
was responsible for handling clinical trial administrative
authorization and regulatory affairs, day-to-day trial
operations management and independent data and
safety monitoring. The CMT also took responsibility
for drug safety and pharmacovigilance tasks. The IMP
sourcing and distribution were managed by a qualified
pharmacist in the coordinating site’s pharmacy service
under the supervision of the CMT.
The STC and CMT worked independently, meeting at
least quarterly for overall supervision of the progress of
the clinical trial, guaranteeing adherence to the planned
timescale, and ensuring that it was conducted, recorded
and reported in accordance with the protocol, SOPs,
GCPs and applicable local regulatory requirements.
Data and safety monitoring
The aim of monitoring is to ensure patient protection, data
quality and trial integrity. To ensure that investigators were
following the protocol, complying with regulatory and
GCP standards and collecting and reporting quality data, a
clinical monitor or clinical research associate appointed by
the trial’s CMT was responsible for supervising study
progress at each investigational site throughout the
duration of the study. Monitoring involved periodic on-site
visits, as well as centralized supervision activities to
identify, prevent or mitigate risks regarding data quality
and for patient protection and trial integrity.
Ethical, deontological and regulatory considerations
Investigators ensured that this study was conducted
in accordance with the principles of the Declaration of
Helsinkiand the International Conference Harmonization
(ICH) Guidelines for GCP and in full conformity with
applicable regulations.
The protocol, informed consent form, participant
information sheets and any applicable documents received
full written ethical and regulatory authority approval. The
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the EU Clinical Trials Register and ClinicalTrials.gov.
All substantial amendments to the original approved
documents also received further approval from the
corresponding ethics committee and regulatory authority.
Once patients met the trial selection criteria, and prior
to study enrollment, investigators obtained their written
informed consent after providing them with appropriate
information about the effects, objectives, methods,
anticipated benefits and potential risks of participation.
Investigators also explained the right to withdraw consent
at any time for any reason. If a patient was unable to read
or provide consent, the patient’s legal representative was
present during the informed consent process and signed
the consent form.
The trial staff ensured that participants’ confidentiality
was preserved. Trial participants were identified by a
code on the eCRF. All study documents and data were
stored securely and were accessible only by the principal
investigator and the authorized staff for purposes related
tothe trial. Individual user identifications and passwords
were necessary to access the trial eCRFs. eCRF data were
encrypted into an SPSS database and stored under the
custody of the trial’s CMT.
The CONSORT guidelines [30] are guaranteed when
publishing the study results in clinical journals and pre-
senting them at national and international conferences.
Discussion
Despite annual vaccination protocols, influenza-associated
complications continue to be an important cause of
hospitalization and death in SOT recipients [3,4]. Although
influenza vaccination has proven to be the most effective
measure to reduce influenza infection after transplantation
[10], SOT recipients are still vulnerable to influenza
infections because their immunological response to
vaccination is lower than that of the general population.
Thus, efforts are needed to improve influenza vaccine
immunogenicity, especially in this vulnerable population
with immunosuppression.
Previous researchers have reported a booster effect of
seasonal influenza vaccine in patients who have baseline
antibody titers [15,20]. In a prospective multicenter study,
investigators observed that patients with baseline titers had
significantly higher sero conversion rates than patients with
no baseline antibody titers (90.9% versus 73.0% respectively,
for the 2009H1N1 strain and 92.2% versus 62.2%, respec-
tively, for the H3N2 strain). Moreover, patients without pre-
existing seroprotection at baseline had lower antibody titers
after influenza vaccination, whereas patients with baseline
antibody titers reached higher GMTs after vaccination [27].
The hypothesis of the present trial is based on these
premises, and we aimed to evaluate the safety and efficacy
of a second, booster dose of influenza vaccine administered5 weeks after the standard seasonal influenza vaccination in
SOT recipients.
Preliminary results based on evaluation of the efficacy of
a booster dose of influenza vaccination in SOT recipients
are controversial. Soesman et al. [17] observed an increased
serological rate in liver transplant recipients after the
second dose of influenza vaccine (80% double-dose versus
67% single-dose), whereas other studies have shown
improved efficacy only after a third dose [18]. Conversely,
other authors have found no benefits of administering a
second vaccine dose [15,31]. Nevertheless, available evidence
is scarce, primarily owing to small sample sizes of the studies,
high baseline seroprotection rates, lack of randomization and
conditions that are not applicable to the present clinical
context, such as different immunosuppression schemes or
different circulating virus serotypes [20,31].
These issues encourage identification of solid base of
research evidence, which is necessary for implementation of
novel strategies to improve influenza prevention in transplant
recipients. Therefore, in the present phase III clinical trial,
we intended to evaluate prospectively the safety and efficacy
of a booster dose of influenza vaccine versus standard single-
dose vaccination in parallel cohorts of SOT recipients.
Conclusions
The solid scientific basis of our hypothesis, the adequate
design of the study and the efforts invested to meet
regulatory requirements and international standards for
clinical trials will be able to produce solid evidence about
the use of a booster dose of influenza vaccination in SOT
recipients. Furthermore, these findings will contribute to
development and implementation of strategies to improve
influenza vaccination response, especially early after
transplantation, where the risk of severe complications
due to influenza infection is higher.
Trial status
At the time this manuscript was submitted the
TRANSGRIPE1-2 trial was closed. The recruitment
period was closed in December 2012 with a total of
499 participants enrolled, and follow-up visits were
completed in December 2013.
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